Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | MMP1 | P03956 | 1/20 | 0.65 |
| ▸ | MMP2 | P08253 | 1/20 | 0.65 |
| ▸ | MMP9 | P14780 | 1/20 | 0.65 |
| ▸ | MMP8 | P22894 | 1/20 | 0.65 |
| ▸ | MMP13 | P45452 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | F2 | P00734 | 3/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.61 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.61 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8131057 | 0.86 | POLB (0.68) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL11122253 | 0.86 | POLB (0.68) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL1341235 | 0.85 | SMN1; SMN2 (0.53) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL1806001 | 0.85 | CA1 (0.65) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL30629805 | 0.85 | CA1 (0.65) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL30184665 | 0.85 | SMN1; SMN2 (0.59) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL358860 | 0.85 | SMN1; SMN2 (0.59) | CA1CA2MMP1MMP2MMP9 | |
| Potassium Ion SCHEMBL14988997 | 0.83 | CA1 (0.63) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL8496089 | 0.83 | CA1 (0.63) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL9817010 | 0.83 | CA1 (0.63) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605392-A1 | METHODS FOR TREATING CANCER | Antares Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024086809-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20170121322-A1 | BET-PROTEIN INHIBITING 3,4-DIHYDROPYRIDO[2,3-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-04 | — | — | US | disclosed |
| EP-3157919-A1 | BET-PROTEIN INHIBITING 3,4-DIHYDROPYRIDO[2,3-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2017-04-26 | — | — | EP | disclosed |
| WO-2015193219-A1 | BET-PROTEIN INHIBITING 3,4-DIHYDROPYRIDO[2,3-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193229-A1 | BET-PROTEIN INHIBITING 1,4-DIHYDROPYRIDO[3,4-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | disclosed |
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2393781-B1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| EP-2435435-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-01-29 | — | — | EP | disclosed |
| US-8536180-B2 | Pyrimidine inhibitors of kinase activity | ABBVIE INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
| US-20070142437-A1 | CHEMICAL COMPOUNDS | BROWN MATTHEW L | 2007-06-21 | — | — | US | disclosed |
| US-7189712-B2 | 1,3-Oxazole compounds for the treatment of cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1730111-A2 | SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005075425-A2 | SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-08-18 | — | — | WO | disclosed |
| EP-0031219-B1 | ANILINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1984-03-07 | — | — | EP | disclosed |
| US-4350691-A | ANTIEMETICS | BEECHAM GROUP LIMITED (GB) | 1982-09-21 | — | — | US | disclosed |
| EP-0031219-A1 | Aniline derivatives | BEECHAM GROUP PLC (GB) | 1981-07-01 | — | — | EP | disclosed |
| US-4052371-A | AZO PIGMENT OR DYE HAVING A NAPHTHYL-QUINAZALONE COUPLING COMPONENT | BASF AKTIENGESELLSCHAFT (DT) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161677-A1 | Bisarylurea derivatives | BRAF, RAF1, NRAS | CA1 4692/4885CA2 3479/4885MMP1 4729/4885 |
| US-20070142437-A1 | CHEMICAL COMPOUNDS | CDK4, CDK2, CDK3 | CA1 4593/4885CA2 2925/4885MMP1 3966/4885 |
| US-20170121322-A1 | BET-PROTEIN INHIBITING 3,4-DIHYDROPYRIDO[2,3-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS | BRD4, BRDT, BRD3 | CA1 4784/4885CA2 4684/4885MMP1 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.